Home » Newsletters » BioWorld Science

BioWorld Science

July 3, 2001

View Archived Issues

Clinical candidate for thrombotic diseases selected by Takeda from dibasic gpIIb/IIIa antagonists

COX-2 inhibitor, leukotriene receptor antagonist and their combination useful for migraine

Further study of zonisamide for migraine/headache prophylaxis appears appropriate

NexMed launches Befar in China

Liver-targeted complexes of cisplatin and bile acids designed by Spanish group

Myocardin, a novel cardiac regulatory gene with potential for heart muscle regeneration

ImClone Systems begins fast track approval process for colorectal cancer agent

Additional beneficial effects emerge for SERM Sch-57068 (EM-652) in preclinical studies

Barr and Duramed agree to merge

Metabolex/Pfizer diabetes partnership gains new focus

SafeScience to create joint venture with Elan for phase II anticancer agent

Exclusivity period for human gene therapeutic consortium expires

Roche licenses levovirin from ICN

ADA news: glycemic control and lipid profiles improve on INS-1 + sulfonylurea in type 2 diabetes

Org-25935 dose-dependently increases striatal glycine levels in rats

Small-molecule LFA-1 antagonist enters phase I studies

CollaGenex launches tablet formulation of Periostat

Novavax seeks approval of Estrasorb in U.S.; expands license agreement with King

New AGE production inhibitor with promise in diabetic nephropathy

NeoTherapeutics adds site to Neotrofin SCI study

Recent patent reveals novel antifungal, antiprotozoal sordaricin derivatives

Selective beta3-adrenoceptor agonists designed at Kissei

Pyrimidine-based inhibitors of CD40 function reported by Sankyo

Brain subtype-specific nicotinic receptor agonists and uses thereof described by Targacept

Potent chymase inhibitors presented by Wakunaga

AHP develops potential anxiolytic and antidepressant agents

Takeda describes heterocyclic compounds that inhibit T-cell proliferation and IL-2 production

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...